Purchase this article with an account.
Anthony S. Basile, Genevieve Glazier, Alice Lee, Li-Ying Jiang, Theodore R. Johnson, Michael J. Shields, Mark Vezina, Venkata R. Doppalapudi; Intravitreal Concentrations of a Near-Infrared Fluorescence–Labeled Biotherapeutic Determined In Situ Using Confocal Scanning Laser Ophthalmoscopy. Invest. Ophthalmol. Vis. Sci. 2011;52(9):6949-6958. doi: 10.1167/iovs.11-7790.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The pharmacokinetics of ophthalmic biotherapeutics are difficult to determine in human vitreous humor. Because of the high transparency of living tissue to near-infrared (NIR) light, the temporal changes in vitreous concentrations of a biomolecule labeled with an NIR fluorescent probe can be monitored in situ with a scanning laser ophthalmoscope (SLO).
A humanized IgG was labeled with the NIR probe IRDye800CW (CVX-4164). Rabbits were given CVX-4164 intravitreally, and NIR fluorescence intensity was measured in the central plane of the vitreous humor with an SLO. Fluorescence intensities were converted to concentrations by using standard curves.
Little background fluorescence was detected, and the minimum detectable concentration of CVX-4164 was <10 nM. Vitreal concentrations of CVX-4164 determined in situ declined with time, with C max ≈ 1 μM and t ½ = 145 hours (112-μg dose). The t ½ of CVX-4164 was approximately three times greater than that of the IRDye800CW alone, whereas the vitreal clearance (CL) and volume of distribution (V ss) of the native dye were approximately 2000- and 550-fold greater than that of the conjugate. CVX-4164 concentrations determined in situ were 2.6 to 4.4 times higher than those determined by ex vivo NIR fluorescence or ELISA in homogenized vitreous humor, reflecting the greater spatial resolution of in situ imaging. Moreover, vitreal concentrations determined in situ were >3 orders of magnitude greater than plasma concentrations of CVX-4164, as determined by ELISA, and had a different kinetic profile.
This study demonstrates the feasibility of determining the pharmacokinetics of intraocular biotherapeutics labeled with NIR fluorescent probes by in situ monitoring.
This PDF is available to Subscribers Only